FDA Approves New Rheumatoid Arthritis Drug
RINVOQ for the treatment of adults with moderately to severely active rheumatoid arthritis has been approved by FDA
AbbVie announced on Aug. 16, 2019 that FDA approved RINVOQ (upadacitinib) for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX-IR). The drug is anticipated to be available in the United States in late August 2019.
"Despite the availability of multiple treatment options with varying mechanisms of action, many patients still do not achieve clinical remission or low disease activity-the primary treatment goals for rheumatoid arthritis," said Roy M. Fleischmann, MD, primary investigator for the Phase III clinical trial program and clinical professor at the University of Texas Southwestern Medical Center in Dallas, in a company press release. "With this FDA approval, RINVOQ has the potential to help additional people living with RA achieve remission who have not yet reached this goal."
Source: AbbVie
Entering New Domains for 3D Printing of Drug Products
April 6th 20253D printing of personalized medications is currently possible under existing compounding regulations, offering enhanced process control through automation. But new legislation coming in 2025 will allow 3D printing as part of a distributed manufacturing framework.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
